JP2015517493A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517493A5 JP2015517493A5 JP2015511470A JP2015511470A JP2015517493A5 JP 2015517493 A5 JP2015517493 A5 JP 2015517493A5 JP 2015511470 A JP2015511470 A JP 2015511470A JP 2015511470 A JP2015511470 A JP 2015511470A JP 2015517493 A5 JP2015517493 A5 JP 2015517493A5
- Authority
- JP
- Japan
- Prior art keywords
- bone
- subject
- cell
- composition
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 210000000988 bone and bone Anatomy 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 239000000090 biomarker Substances 0.000 claims 4
- 239000007943 implant Substances 0.000 claims 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 239000000411 inducer Substances 0.000 claims 3
- 230000011164 ossification Effects 0.000 claims 3
- 230000004072 osteoblast differentiation Effects 0.000 claims 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 230000008468 bone growth Effects 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000001582 osteoblastic effect Effects 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 claims 1
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 claims 1
- 229940122280 Cytochrome P450 inhibitor Drugs 0.000 claims 1
- 241000027355 Ferocactus setispinus Species 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 claims 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims 1
- 101001023988 Homo sapiens Growth/differentiation factor 5 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 102000004067 Osteocalcin Human genes 0.000 claims 1
- 108090000573 Osteocalcin Proteins 0.000 claims 1
- 102000003982 Parathyroid hormone Human genes 0.000 claims 1
- 108090000445 Parathyroid hormone Proteins 0.000 claims 1
- 239000002617 bone density conservation agent Substances 0.000 claims 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims 1
- 230000034127 bone morphogenesis Effects 0.000 claims 1
- 230000002308 calcification Effects 0.000 claims 1
- 230000003185 calcium uptake Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 230000000921 morphogenic effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000002188 osteogenic effect Effects 0.000 claims 1
- 239000000199 parathyroid hormone Substances 0.000 claims 1
- 229960001319 parathyroid hormone Drugs 0.000 claims 1
- 235000013024 sodium fluoride Nutrition 0.000 claims 1
- 239000011775 sodium fluoride Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- IYSAORWDWNDPMT-KBUDBUIVSA-N CCCCCCC(C)(C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1C(C1)[C@H]2C(C)(CC[C@@H](C2)O)[C@H]2[C@H]1OC(CCC(NCCOCCOCC(Nc(c(O)c1C(N)=O)ccc1OC)=O)=O)=O Chemical compound CCCCCCC(C)(C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1C(C1)[C@H]2C(C)(CC[C@@H](C2)O)[C@H]2[C@H]1OC(CCC(NCCOCCOCC(Nc(c(O)c1C(N)=O)ccc1OC)=O)=O)=O IYSAORWDWNDPMT-KBUDBUIVSA-N 0.000 description 1
- XTMLPZNCOKFONO-DXNIEGDMSA-N CCCCCC[C@@](C)([C@@H](CC1)[C@@](C)(CC2)[C@@H]1C(C1)[C@H]2[C@@](C)(CC[C@@H](C2)O)[C@H]2[C@H]1OC(CCC(NCCOCCOCC(Nc(c(O)c1C(N)=O)ccc1OC)=O)=O)=O)O Chemical compound CCCCCC[C@@](C)([C@@H](CC1)[C@@](C)(CC2)[C@@H]1C(C1)[C@H]2[C@@](C)(CC[C@@H](C2)O)[C@H]2[C@H]1OC(CCC(NCCOCCOCC(Nc(c(O)c1C(N)=O)ccc1OC)=O)=O)=O)O XTMLPZNCOKFONO-DXNIEGDMSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261643776P | 2012-05-07 | 2012-05-07 | |
| US61/643,776 | 2012-05-07 | ||
| PCT/US2013/032650 WO2013169397A1 (en) | 2012-05-07 | 2013-03-15 | Novel oxysterol analogue, oxy149, induces osteogenesis and hedgehog signaling and inhibits adipogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015517493A JP2015517493A (ja) | 2015-06-22 |
| JP2015517493A5 true JP2015517493A5 (enExample) | 2016-05-26 |
Family
ID=49551139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511470A Pending JP2015517493A (ja) | 2012-05-07 | 2013-03-15 | 新規オキシステロールアナログｏｘｙ１４９は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20150140059A1 (enExample) |
| EP (1) | EP2847205A4 (enExample) |
| JP (1) | JP2015517493A (enExample) |
| KR (1) | KR20150008160A (enExample) |
| CN (1) | CN104507951B (enExample) |
| AU (1) | AU2013260057A1 (enExample) |
| CA (1) | CA2872734A1 (enExample) |
| IN (1) | IN2014DN09804A (enExample) |
| RU (1) | RU2014149153A (enExample) |
| WO (1) | WO2013169397A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005020928A2 (en) | 2003-08-29 | 2005-03-10 | The Regents Of The University Of California | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins |
| CA2643732C (en) | 2006-02-27 | 2012-08-21 | The Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| JP2011505357A (ja) | 2007-12-03 | 2011-02-24 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | ヘッジホッグシグナル伝達、骨誘導、抗脂肪生成、及びｗｎｔシグナル伝達を活性するためのオキシステロール |
| WO2013169399A1 (en) | 2012-05-07 | 2013-11-14 | The Regents Of The University Of California | Oxysterol analogue oxy133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis |
| WO2014179756A1 (en) * | 2013-05-02 | 2014-11-06 | The Regents Of The University Of California | Bone-selective osteogenic oxysterol-bone targeting agents |
| GB201319776D0 (en) * | 2013-11-08 | 2013-12-25 | Allecra Therapeutics Sas | Compound |
| JP6530056B2 (ja) | 2014-05-02 | 2019-06-12 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア | 骨選択的骨形成オキシステロールビスホスホネート類似体 |
| CN107427526B (zh) | 2014-12-09 | 2021-08-03 | 华沙整形外科股份有限公司 | 涉及甾醇的化合物和方法 |
| US10632230B2 (en) | 2015-07-10 | 2020-04-28 | Warsaw Orthopedic, Inc. | Implants having a high drug load of an oxysterol and methods of use |
| US12171909B2 (en) | 2015-07-10 | 2024-12-24 | Warsaw Orthopedic, Inc. | Implants having a drug load of an oxysterol and methods of use |
| US9637514B1 (en) * | 2015-10-26 | 2017-05-02 | MAX BioPharma, Inc. | Oxysterols and hedgehog signaling |
| US20170275330A1 (en) * | 2016-03-28 | 2017-09-28 | Warsaw Orthopedic, Inc. | Polymorphic forms of an oxysterol and methods of making them |
| US9987290B2 (en) * | 2016-03-28 | 2018-06-05 | Warsaw Orthopedic, Inc. | Methods for the separation and detection of an oxysterol |
| US10688222B2 (en) | 2016-11-21 | 2020-06-23 | Warsaw Orthopedic, Inc. | Lyophilized moldable implants containing an oxysterol |
| US11384114B2 (en) * | 2016-12-09 | 2022-07-12 | Warsaw Orthopedic, Inc. | Polymorphic forms of an oxysterol and methods of making them |
| US10294264B2 (en) * | 2017-04-21 | 2019-05-21 | Warsaw Orthopedic, Inc. | Oxysterol-therapeutic agent derivative for bone healing |
| US10434106B2 (en) | 2017-05-19 | 2019-10-08 | Warsaw Orthopedic, Inc. | Oxysterol-statin compounds for bone growth |
| US11464888B2 (en) | 2017-06-12 | 2022-10-11 | Warsaw Orthopedic, Inc. | Moldable formulations containing an oxysterol in an acellular tissue matrix |
| WO2019048898A1 (en) | 2017-09-05 | 2019-03-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION |
| EP3833377B1 (en) * | 2018-08-10 | 2023-11-22 | Alexion Pharmaceuticals, Inc. | Bone healing at implants using alkaline phosphatase |
| BR112023016048A2 (pt) | 2021-02-12 | 2023-11-14 | Alexion Pharma Inc | Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06329697A (ja) * | 1993-03-25 | 1994-11-29 | Kowa Co | 骨疾患治療剤 |
| WO2000066613A1 (en) * | 1999-04-30 | 2000-11-09 | Research Corporation Technologies, Inc. | Bone targeting agents for osteoporosis |
| JP2007517041A (ja) * | 2003-12-24 | 2007-06-28 | ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション | 骨障害および代謝性疾患の診断、治療および予防用の化合物 |
| CA2643732C (en) * | 2006-02-27 | 2012-08-21 | The Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| WO2008103951A1 (en) * | 2007-02-23 | 2008-08-28 | University Of Louisville Research Foundation, Inc | Methods and compounds for the targeted delivery of agents to bone for interaction therewith |
| US20080221070A1 (en) * | 2007-03-06 | 2008-09-11 | Pierce William M | Methods and compounds for the targeted delivery of agents to bone for interaction therewith |
| JP2011505357A (ja) * | 2007-12-03 | 2011-02-24 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | ヘッジホッグシグナル伝達、骨誘導、抗脂肪生成、及びｗｎｔシグナル伝達を活性するためのオキシステロール |
| WO2012024581A2 (en) * | 2010-08-20 | 2012-02-23 | Fate Therapeutics, Inc. | Oxysterol compounds |
| WO2012024584A2 (en) * | 2010-08-20 | 2012-02-23 | Fate Therapeutics, Inc. | Oxysterol compounds |
| WO2012024583A2 (en) * | 2010-08-20 | 2012-02-23 | Fate Therapeutics, Inc. | Oxysterol compounds |
-
2013
- 2013-03-15 WO PCT/US2013/032650 patent/WO2013169397A1/en not_active Ceased
- 2013-03-15 JP JP2015511470A patent/JP2015517493A/ja active Pending
- 2013-03-15 RU RU2014149153A patent/RU2014149153A/ru not_active Application Discontinuation
- 2013-03-15 CA CA2872734A patent/CA2872734A1/en not_active Abandoned
- 2013-03-15 CN CN201380033489.6A patent/CN104507951B/zh not_active Expired - Fee Related
- 2013-03-15 KR KR20147033927A patent/KR20150008160A/ko not_active Withdrawn
- 2013-03-15 AU AU2013260057A patent/AU2013260057A1/en not_active Abandoned
- 2013-03-15 EP EP13787286.7A patent/EP2847205A4/en not_active Withdrawn
- 2013-03-15 US US14/399,105 patent/US20150140059A1/en not_active Abandoned
-
2014
- 2014-11-19 IN IN9804DEN2014 patent/IN2014DN09804A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517493A5 (enExample) | ||
| JP2015518493A5 (enExample) | ||
| RU2014149153A (ru) | Новый аналог оксистерола, oxy149, индуцирует остеогенез и сигнальный путь hedgehog и ингибирует липогенез | |
| RU2014149164A (ru) | Аналог оксистерола oxy133 индуцирует остеогенез и сигнальный путь hedgehog и ингибирует липогенез | |
| Zhao et al. | The promotion of bone healing by progranulin, a downstream molecule of BMP-2, through interacting with TNF/TNFR signaling | |
| Rutten et al. | Low-intensity pulsed ultrasound increases bone volume, osteoid thickness and mineral apposition rate in the area of fracture healing in patients with a delayed union of the osteotomized fibula | |
| Shen et al. | Pulsed electromagnetic fields stimulation affects BMD and local factor production of rats with disuse osteoporosis | |
| Wang et al. | Summary of the various treatments for osteonecrosis of the femoral head by mechanism: A review | |
| JP2006503819A5 (enExample) | ||
| CA2643732A1 (en) | Oxysterol compounds and the hedgehog pathway | |
| Tao et al. | Silibinin can promote bone regeneration of selenium hydrogel by reducing the oxidative stress pathway in ovariectomized rats | |
| KR20080114717A (ko) | 골다공증의 치료를 위한 ｇｓｋ-３ 억제제 | |
| ES3041577T3 (en) | Compositions comrising an opioid growth factor receptor (ogfr) antagonist for use in promoting bone formation and in the treatment of cancer. | |
| Li et al. | Selenium-modified calcium phosphate cement can accelerate bone regeneration of osteoporotic bone defect | |
| Bradaschia-Correa et al. | Ecto-5′-nucleotidase (CD73) regulates bone formation and remodeling during intramembranous bone repair in aging mice | |
| Chamberlain et al. | A review of the cellular and molecular effects of extracorporeal shockwave therapy | |
| Crous et al. | The signalling effects of photobiomodulation on osteoblast proliferation, maturation and differentiation: a review | |
| Wang et al. | Signalling pathways underlying pulsed electromagnetic fields in bone repair | |
| Zhang et al. | Negative pressure technology enhances bone regeneration in rabbit skull defects | |
| Mansoori et al. | Combination of PTH (1-34) with anti-IL17 prevents bone loss by inhibiting IL-17/N-cadherin mediated disruption of PTHR1/LRP-6 interaction | |
| Choi et al. | Betulinic acid synergically enhances BMP2-induced bone formation via stimulating Smad 1/5/8 and p38 pathways | |
| Sritharan et al. | The synergistic effects of IL-6/IL-17A promote osteogenic differentiation by improving OPG/RANKL ratio and adhesion of MC3T3-E1 cells on hydroxyapatite | |
| Singh et al. | Biological basis of distraction osteogenesis–a review | |
| ES2701675T3 (es) | Irisina para el cuidado y la prevención de la osteoporosis | |
| Rajfer et al. | Prevention of osteoporosis in the ovariectomized rat by oral administration of a nutraceutical combination that stimulates nitric oxide production |